Navigation Links
Cempra to Present Data on Solithromycin's (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
Date:4/26/2013

(from an enrollment of 28) including from cervical, urethral, rectal and pharyngeal infection sites
  • Solithromycin was well tolerated and was accompanied by only mild gastrointestinal effects
  • Abstract P 1640, 1:30-2:30 p.m. CEST: In vitro and intracellular activity of solithromycin (CEM-101) against clinical isolates of Legionella pneumophila

    J. Mallegol, P. Fernandes, R. Melano, C. Guyard

    • Legionella pneumophila is an important respiratory pathogen
    • Azithromycin and fluoroquinolones are the currently-recommended treatments but resistance to both antibiotics is increasing; cephalosporins are ineffective
    • Solithromycin demonstrated higher in vitro potency against all L. pneumophila isolates than azithromycin

    Abstract P 1593, 1:30-2:30 p.m. CEST: Analysis of solithromycin bactericidal activity against vancomycin-susceptible and vancomycin-resistant enterococci

    J Deane, C. Opiela, D Sahm, K. Keedy, A. Sheets, P. Fernandes

    • Linezolid was the last antibiotic approved to treat enterococcal infections
    • MICs for solithromycin were relatively low compared to linezolid suggesting that a macrolide could be an option to treat these infections
    • Although neither solithromycin nor linezolid demonstrated bactericidal activity, solithromycin almost eradicated one strain, suggesting that solithromycin's spectrum of activity may differ from those of older macrolides and ketolides.

    Abstract P 1638, 1:30-2:30 p.m. CEST: In vitro activity of solithromycin (CEM-101) among azithromycin resistant and susceptible Mycoplasma genitalium strains

    J.S. Jensen , P. Fernandes and M. Unemo

    • Mycoplasma genitalium is a well-known and important cause of sexu
      '/>"/>

    SOURCE Cempra, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
    2. Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
    3. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
    4. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
    5. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
    6. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
    7. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
    8. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
    9. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
    10. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
    11. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... , Sept. 30, 2014 ... CHDX ) today announced the completion of its ... $24.00 per share in cash.  Healthy Harmony is an ... ("Fosun") and Ms. Roberta Lipson , the CEO ... agreement was adopted by Chindex,s stockholders at a special ...
    (Date:9/30/2014)... ANGELES , Sept. 30, 2014 ... biopharmaceutical research and development company specializing in oncology, ... 2b clinical trial evaluating aldoxorubicin compared to topotecan ... (SCLC) who have relapsed or were refractory to ... the widely-used chemotherapeutic agent, doxorubicin. CytRx has received ...
    (Date:9/29/2014)... N.Y. and PARIS , ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... an investigational therapy that blocks IL-4 and IL-13 signaling, ... moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did ... data suggest the potential of dupilumab for use in ...
    Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7
    ... U.S. Dept. of Defense Continues Study of Copper ... Infections and Improving Indoor Air Quality, NEW ... clinical trails determining the,antimicrobial effectiveness of copper, brass ... Association, announced CDA President Andrew G.,Kireta Sr. ...
    ... Serious Adverse Reactions, BERKELEY HEIGHTS, N.J., Nov. ... findings from the initial clinical,dosing of G4544, the ... treatment for diseases associated with accelerated bone loss. ... volunteers, has shown good,tolerance with oral bioavailability of ...
    Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
    (Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
    (Date:9/30/2014)... If you were to create a list ... it say? Would you place a high value on charisma? ... create a leadership “wish list,” the truth is that just ... there different types of leaders. But if good leaders come ... programs that account for this kind of diversity? , ...
    (Date:9/30/2014)... Lexington, KY (PRWEB) September 30, 2014 ... million people in the United States alone have sleep ... treated; and of those treated, many cannot tolerate their ... pressure supplied through a nasal mask) – which supports ... good night’s sleep has become especially valuable, and increasingly ...
    (Date:9/30/2014)... is proud to announce the release of The ... by Frank Guglielmo and Sudhanshu Palsule ... their leadership coaching experience to introduce Social Leadership – a ... that leaders must adopt in order to thrive in today’s ... review of The Social Leader in Dialogue Reviews. , Author ...
    (Date:9/30/2014)... IL (PRWEB) September 30, 2014 ... clash,” opened Bryan W. Brickner, “and it’s about ... Political Cannabinoid Science , new on the Bryan ... research from the National Institutes of Health (PubMed). ... regarding: de-homeostatic sleep disturbances, REM transitions, aging with ...
    Breaking Medicine News(10 mins):Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Personality Plays a Key Role in Leadership Development 2Health News:Personality Plays a Key Role in Leadership Development 3Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2
    ... to have their blood sugar, blood pressure, and cholesterol ... a high-quality Medicare plan, researchers reported Tuesday. ... Medical Association, show that racial disparities are common throughout ... Amal N. Trivedi of Brown University in Providence, Rhode ...
    ... about personalized medicine enabled through genetic testing, slated to ... would not only involve forecasting the presence of a ... but will also enable early prevention strategies. ... cardiovascular diseases, but will unravel the genetic blue prints ...
    ... of folic acid every day could have better chance of getting ... form of vitamin B is used in our bodies to make ... body before she is pregnant, it can help prevent major birth ... study involving more than 18,000 women for the first time revealed ...
    ... Regular exercise combined with nicotine replacement therapy could help ... colleagues at the Otto Wagner Hospital// in Vienna enrolled ... nicotine-replacement therapy, reported the online edition of health magazine ... be quitters enrolled in an exercise programme., ,The ...
    ... to a recent study, women with a twin are at upto ... without one//. ,The study was conducted on over 800 ... premature ovarian failure (POF) at the age of 40 was 3-5 ... causes the ovaries to shut down ten years or earlier than ...
    ... and toddlers, reports a major study conducted on the side effects ... government proposed immunization for all kids of the age 6 months ... a sharp rise in the number of children getting vaccinated. This ... 2 years as often as the old people. ,This ...
    Cached Medicine News:Health News:Medicare Marked by Widespread Racial disparities 2Health News:Folic Acid Supplements Could Help Conception 2
    ... system includes: Mx3005P instrument and custom ... five (5) filters. The standard filter ... HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 ... notebook computer, Mx3005P analysis software, Beacon ...
    ... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
    ... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
    ... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
    Medicine Products: